CHMA - Chiasma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.5700
+0.0200 (+0.44%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.5500
Open4.5700
Bid4.4000 x 800
Ask4.8300 x 1000
Day's Range4.5250 - 4.7000
52 Week Range3.8790 - 9.2500
Volume159,262
Avg. Volume306,577
Market Cap192.015M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-1.0870
Earnings DateMar 05, 2020 - Mar 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.60
  • Wall Street Pros: These 3 Stocks Can Double Next Year
    TipRanks

    Wall Street Pros: These 3 Stocks Can Double Next Year

    Let’s not complicate matters. Broken down into the most basic elements, it’s all very simple: investors want to put their hard earned cash in a place where they will return to after a period of time, and find that, viola! There is more money in said place than they had initially put in.But what is the best way to go about it? There are countless options, for sure, but as anyone, in any field will tell you, listening to the pros’ advice is one well-trodden, tried and tested path.TipRanks tracks the recommendations of over 6,000 such pros pounding the investing pavement of Wall Street on a daily basis. With this in mind, we used the platform to take a look at 3 tickers the experts on the Street think could potentially double in value over the next year. Let’s jump right in.Phasebio Pharmaceuticals Inc. (PHAS)If you’re looking to double your investment over a 12-month period, then the healthcare industry is a good place to begin your search. The volatile sector often sees biotechs double their value in a week, or even a day, never mind a year. The sector comes, though, with added risk attached to it, as what can be sent soaring majestically following positive data or regulatory approval can also be dumped unceremoniously by investors, should negative news make the headlines.With this in mind, we turn to Phasebio Pharmaceuticals. This micro-cap is focused on developing novel therapies for orphan diseases with a strong emphasis on cardiopulmonary indications.The company’s lead candidate is PB2452, a monoclonal antibody antigen-binding fragment intended to reverse the antiplatelet effects of AstraZeneca's blood thinner Brilinta. The drug is currently in a Phase 2b trial, with plans to initiate a pivotal Phase 3 trial in this year’s first quarter. The trial will support a Biologics License Application (BLA) for PB2452 in both major bleeding and urgent surgery indications.Following a successful Phase 1 trial last year, the FDA granted the drug breakthrough therapy designation (BTD) status. If the rest of the trials go well, PB2452 should hit the market by no later than 2022.Citigroup’s Joel Beatty believes Phasebio stock is “overly cheap”. The analyst thinks Phasebio is the most undervalued stock in Citi’s SMid-biotech coverage universe. “Although we project that Phase 3 results for PB2452 will come in 2H21 (beyond the current cash runway into ~1Q21), we see potential for enrollment updates throughout 2021 to provide some upside,” he said.Bottom line? Beatty maintained his Buy rating on Phasebio, along with a price target of $25. This implies potential upside of a massive 357%. (To watch Beatty’s track record, click here)The rest of the Street is hardly any less enthusiastic. 6 Buy ratings add up to a Strong Buy consensus rating. The average price target hits $21, implying potential gains of a massive 274%. (See Phasebio price targets and analyst ratings on TipRanks) GlycoMimetics (GLYC)Let’s stay in the biotech sector and look at the dramatic effect disappointing trial results can have on a stock.In August last year, biotech GlycoMimetics licensee Pfizer reported negative results from the Phase 3 RESET trial of Rivipansel, which demonstrated that it failed to meet the primary endpoint of the study. What happened next, you ask? Shares of GLYC tumbled in a day, shedding 69% of their value. Ouch. The share price slowly clawed its way out of the doldrums throughout the rest of the year, but so far in 2020, the stock is down by 17%.Nevertheless, Stifel Nicolaus’ Stephen Willey is a fan of GLYC. The 5-star analyst claims the oncology-focused company’s candidate for the treatment of patients with acute myeloid leukemia (AML), uproleselan/GMI-1687 (formerly GMI-1271), is a “highly-differentiated and potentially best-in-class therapy for these limited-option patients.” He argues that the delay of Phase 3 top-line results has no bearing on his longer-term outlook for the drug.According to Willey, the Phase 1/2 uproleselan data in relapsed/refractory and newly-diagnosed AML, which demonstrated a marked improvement in both the magnitude and depth of patient responses and the mitigation of chemotherapy-induced toxicity, bodes well for the candidate’s prospects.Additionally, Willey feels the current valuation ignores other earlier-stage pipeline opportunities. Taking all this into consideration, then, Willey reiterated a Buy rating and $14 price target on the biotech. Should his thesis play out, investors will pocket a hefty 220% gain over the next year. (To watch Willey’s track record, click here)Similarly, the majority of the Street takes a bullish approach when it comes to GLYC. Out of 5 analysts tracked over the last three months, 4 recommend a Buy while one suggests a Hold. At the average price target of $11.50, investors will take home a 161% gain should the figure be met in the months ahead. (See GlycoMimetics price targets and analyst ratings on TipRanks) Chiasma (CHMA)The third ticker on our list is a fellow micro-cap from the biotech space. Chiasma’s focus is on improving the lives of patients suffering from rare and serious chronic diseases. Its goal is to develop oral medications that are currently only available as injections through the use of its Transient Permeability Enhancer (TPE) technology platform.The company is developing octreotide capsules, known as Mycapssa, for the treatment of adult patients with acromegaly, a disorder that results from excess growth hormone. Symptoms of the disease can include the enlargement of the hands and feet, along with the forehead, jaw and nose, possibly leading to type 2 diabetes, sleep apnea and high blood pressure. The condition is extremely rare and affects about 6 out of 100,000 people.Chiasma received the dreaded CRL (complete response letter) for the drug in April 2016, which cited the need for another clinical trial. It resubmitted its Mycapssa (octreotide) application in December, which the FDA has accepted for review. A decision on the application is expected mid-year. If all goes well, commercial launch should ramp up in Q4.Piper Sandler’s Edward Tenthoff is confident that Mycapssa will receive US approval, noting that manufacturing preparation is underway ahead of its potential launch. Not to mention the 5-star analyst believes that Chiasma remains on course to report top-line data from its Phase 3 MPOWERED study in Europe during Q4 to support EMA approval.As a result, Tenthoff kept his Overweight rating on Chiasma along with a price target of $11 as is. Investors will be celebrating returns of a hefty 123% should the target be met. (To watch Tenthoff’s track record, click here)The chronic disease fighter’s Strong Buy consensus rating breaks down into Buy ratings only – 4, as it happens. The average price target of $12.75 implies potential upside of 161%. (See Chiasma stock analysis on TipRanks)

  • Does Chiasma, Inc. (NASDAQ:CHMA) Have A High Beta?
    Simply Wall St.

    Does Chiasma, Inc. (NASDAQ:CHMA) Have A High Beta?

    Anyone researching Chiasma, Inc. (NASDAQ:CHMA) might want to consider the historical volatility of the share price...

  • GlobeNewswire

    Chiasma Announces FDA Acceptance of MYCAPSSA® New Drug Application Resubmission

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) resubmission for its oral octreotide capsules investigational product candidate, conditionally trade named MYCAPSSA®. Chiasma is developing MYCAPSSA for the maintenance treatment of adults with acromegaly.

  • GlobeNewswire

    Chiasma Provides Corporate Update and Previews 2020 Milestones

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reviewed its 2019 highlights and previewed its anticipated 2020 corporate milestones. MYCAPSSA New Drug Application (NDA) Resubmitted to FDA: On December 26, Chiasma resubmitted its NDA to the U.S. Food and Drug Administration (FDA) for its investigational octreotide capsules product candidate, MYCAPSSA, for the maintenance treatment of adults with acromegaly.

  • Benzinga

    The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ) Ardelyx ...

  • GlobeNewswire

    Chiasma Added to NASDAQ Biotechnology Index

    NEEDHAM, Mass., Dec. 19, 2019 -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • Hedge Funds Have Never Been This Bullish On Chiasma Inc (CHMA)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Chiasma Inc (CHMA)

    After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]

  • GlobeNewswire

    Chiasma to Present at the Piper Jaffray 31st Annual Healthcare Conference

    WALTHAM, Mass., Nov. 26, 2019 -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • Thomson Reuters StreetEvents

    Edited Transcript of CHMA earnings conference call or presentation 5-Nov-19 10:00pm GMT

    Q3 2019 Chiasma Inc Earnings Call

  • GlobeNewswire

    Chiasma to Present at the 13th Acromegaly Consensus Conference

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that William Ludlam, M.D., Ph.D., Senior Vice President of Clinical Development and Medical Affairs, will present at the 13th Acromegaly Consensus Conference, to be held from November 17th-19th in Fort Lauderdale, Florida. Dr. Ludlam is scheduled to present on Sunday, November 17th. “We are pleased to be sharing positive top-line data from our Phase 3 CHIASMA OPTIMAL trial of MYCAPSSA®, that is being developed for the maintenance treatment of adult acromegaly patients, at the conference this year,” said Dr. William Ludlam.

  • Hedge Funds Have Never Been More Bullish On Chiasma Inc (CHMA)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Chiasma Inc (CHMA)

    Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]

  • GlobeNewswire

    Chiasma Reports Third Quarter 2019 Results

    CHIASMA OPTIMAL trial, conducted under SPA and designed to support FDA approval, met the primary and all secondary endpoints MYCAPSSA® NDA on track for submission by year-end.

  • GlobeNewswire

    Chiasma Supports Acromegaly Awareness Day

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today recognizes November 1st as Acromegaly Awareness Day. “We recognize Acromegaly Awareness Day each year to call attention to this rare and debilitating disease, and to highlight the significant treatment burdens faced by patients and their families and the need for new maintenance treatment options,” said Raj Kannan, Chief Executive Officer of Chiasma. “Today, the Acromegaly Community is pleased to recognize Acromegaly Awareness Day, which reflects on our mission to provide an emotional and communal support network for people touched by acromegaly,” said Jill Sisco, President of the Acromegaly Community.

  • GlobeNewswire

    Chiasma to Report Third Quarter Financial Results on November 5, 2019

    WALTHAM, Mass., Oct. 29, 2019 -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • We're Not Very Worried About Chiasma's (NASDAQ:CHMA) Cash Burn Rate
    Simply Wall St.

    We're Not Very Worried About Chiasma's (NASDAQ:CHMA) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    Chiasma to Present at the Cantor 2019 Global Healthcare Conference

    WALTHAM, Mass., Sept. 25, 2019 -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • TheStreet.com

    3 Small Biotechs With Favorable Risk Vs. Reward Profiles

    BioDelivery Sciences International, Chiasma Inc. and TherapeticsMD all feature promising treatments.

  • What Makes Chiasma (CHMA) a New Buy Stock
    Zacks

    What Makes Chiasma (CHMA) a New Buy Stock

    Chiasma (CHMA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • What Kind Of Shareholder Owns Most Chiasma, Inc. (NASDAQ:CHMA) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most Chiasma, Inc. (NASDAQ:CHMA) Stock?

    A look at the shareholders of Chiasma, Inc. (NASDAQ:CHMA) can tell us which group is most powerful. Institutions will...

  • GlobeNewswire

    Chiasma Hosting Key Opinion Leader Meeting on Maintenance Therapy of Adult Patients with Acromegaly

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, will host a Key Opinion Leader (KOL) breakfast on maintenance therapy of adult patients with acromegaly on Thursday, September 12, 2019 in New York City. The meeting will feature a presentation by KOL Susan Samson, MD, PhD, from the Pituitary Center at Baylor St. Luke's Medical Center, and Jill Sisco, from the Acromegaly Community, who will discuss the current treatment landscape, as well as the unmet medical need for treating adults with acromegaly.

  • Thomson Reuters StreetEvents

    Edited Transcript of CHMA earnings conference call or presentation 8-Aug-19 9:00pm GMT

    Q2 2019 Chiasma Inc Earnings Call

  • Chiasma (CHMA) Upgraded to Buy: Here's Why
    Zacks

    Chiasma (CHMA) Upgraded to Buy: Here's Why

    Chiasma (CHMA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Chiasma Inc (CHMA) Q2 2019 Earnings Call Transcript
    Motley Fool

    Chiasma Inc (CHMA) Q2 2019 Earnings Call Transcript

    CHMA earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    Chiasma Reports Second Quarter 2019 Results

    Announces positive data from Phase 3 CHIASMA OPTIMAL trial; MYCAPSSA® NDA submission expected by year-end 2019 with an expected six-month PDUFA review time period MPOWERED.

  • GlobeNewswire

    Chiasma to Report Second Quarter Financial Results on August 8, 2019

    WALTHAM, Mass., Aug. 01, 2019 -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.